What to do if there is resistance to the third-generation targeted drug platinib

Platinib, as a third-generation targeted drug, has shown significant efficacy in the treatment of cancer. However, as treatment progresses, some patients may develop drug resistance, resulting in reduced or ineffective drug efficacy. Faced with platinib resistance, doctors and patients need to adopt a series of strategies to deal with it.

When platinib resistance is suspected, resistance should first be confirmed through relevant examinations and tests. This may include genetic testing, imaging tests, and more to assess tumor growth and the presence of new mutations. These examinations help doctors understand the patient's condition more accurately and provide a basis for formulating subsequent treatment plans.

Based on the results of genetic testing, doctors may recommend that patients switch to other targeted drugs that target specific gene mutations. For example, if other available gene mutation targets are detected, corresponding targeted drugs can be selected for treatment. In cases of resistance to targeted drugs, combination chemotherapy or radiotherapy may be an effective treatment strategy. These traditional treatment methods can produce synergistic effects with targeted drugs to enhance the killing effect on tumor cells.

Immunotherapy works by activating the patient's own immune system to attack tumor cells. For some patients, immunotherapy may be an effective option after drug resistance. For example, the use of drugs such as immune checkpoint inhibitors can help restore the immune system's ability to fight tumors.

Supportive care and symptom management are equally important in dealing with drug resistance. This includes providing nutritional support, psychological support, and treatment for specific symptoms (such as pain, nausea, etc.). These measures help improve patients’ quality of life and help them better cope with the challenges of treatment.